Advaxis' Clinical Trial Survival Data Significantly Exceeds The National Cancer Institute's Median Survival Statistic

This news article has expired. Below you will find a short description about the news article and comments that were left by CancerCompass users.

Advaxis, Incorporated, has updated survival data for its Phase I clinical trial (Trial) of its live Listeria vaccine ADXS11-001(formerly named Lovaxin-C) in the treatment of advanced, metastatic cervix patients who have failed first line cytotoxic therapy.

 

0 Comments

You must be logged in to post comments.

We care about your feedback. Let us know how we can improve your CancerCompass experience.